Mgr. Karla Plevová, Ph.D.
Head of the research group, Karla Plevová Research Group: Genomics of Immune Cells
correspondence Address:
Jihlavská 340/20, 625 00 Brno
office: bldg. E35/258
Kamenice 753/5
625 00 Brno
phone: | +420 532 23 4396 |
---|---|
e‑mail: | |
web: | https://genomika.med.muni.cz/research/research-groups/karla-plevova-group/about-us |
social and academic networks: |
---|
Total number of publications: 359
2013
-
CLL: Different ages, dfferent antigen receptor profiles
Year: 2013, type: Conference abstract
-
Cytogenetické vyšetření lymfocytů periferní krve po stimulaci IL 2 a CpG oligonukleotidem DSP30 u pacientů s chronickou lymfocytární leukemiíridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: A prospective analysis.
Klinická onkologie, year: 2013, volume: 26, edition: 4
-
Differential distribution of recurrent gene mutations in subsets of chronic lymphocytic leukemia patients with stereotyped B-cell receptros: results from a multicenter project of the european research initiative on CLL in a series of 2482 cases
Year: 2013, type: Conference abstract
-
Distinct frequency and profiles of TP53 gene mutations in CLL subgroups with distinct antigen receptors: Evidence for antigen-driven selection of genomci aberrations.
Year: 2013, type: Conference abstract
-
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
Leukemia, year: 2013, volume: 27, edition: 11, DOI
-
Dráha Wnt/PCP ovlivňuje kromě patogeneze chronické lymfocytární leukemie i vývoj B-lymfocytů
Year: 2013, type: Conference abstract
-
Klonální evoluce a selekce mutací TP53 v relapsu chronické lymfocytární leukémie
Year: 2013, type:
-
Metodou RT-qPCR k predikci vývoje chronické lymfocytární leukémie (CLL)
Year: 2013, type: Conference abstract
-
Molekulární biologie CLL - význam molekulárních prognostických faktorů
Year: 2013, type:
-
Ofatumumab added to dexamethasone in patients with relapsed of refractory chronic lymphocytc leukemia. Results from a phase II study of the czech leukemia study group for life
Year: 2013, type: Conference abstract